OA11294A - Branched alkoxy-substituted 2-aminopyridines as nos inhibitors. - Google Patents

Branched alkoxy-substituted 2-aminopyridines as nos inhibitors. Download PDF

Info

Publication number: OA11294A
Authority: OA; OAPI
Prior art keywords: disease; phenyl; alkyl; pyridin; shock
Prior art date: 1997-08-28

Application number

OA1200000053A

Other languages

English (en)

Inventor

Lowe John Adams Iii

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-28

Filing date

2000-02-25

Publication date

2003-10-22

2000-02-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-10-22 Publication of OA11294A publication Critical patent/OA11294A/en

Links

239000003112 inhibitor Substances 0.000 title abstract description 6
150000003930 2-aminopyridines Chemical class 0.000 title description 2
102000008299 Nitric Oxide Synthase Human genes 0.000 claims abstract description 24
108010021487 Nitric Oxide Synthase Proteins 0.000 claims abstract description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
150000001875 compounds Chemical class 0.000 claims description 80
-1 chloro, fluoro, bromo, iodo Chemical group 0.000 claims description 26
125000000217 alkyl group Chemical group 0.000 claims description 18
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 16
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 16
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
208000002193 Pain Diseases 0.000 claims description 14
230000001154 acute effect Effects 0.000 claims description 14
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 14
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 14
241000124008 Mammalia Species 0.000 claims description 13
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 13
125000001424 substituent group Chemical group 0.000 claims description 13
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 10
206010040070 Septic Shock Diseases 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
230000036303 septic shock Effects 0.000 claims description 9
230000035939 shock Effects 0.000 claims description 9
208000030507 AIDS Diseases 0.000 claims description 8
208000019901 Anxiety disease Diseases 0.000 claims description 8
206010009900 Colitis ulcerative Diseases 0.000 claims description 8
208000011231 Crohn disease Diseases 0.000 claims description 8
206010012335 Dependence Diseases 0.000 claims description 8
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 8
208000010412 Glaucoma Diseases 0.000 claims description 8
206010019196 Head injury Diseases 0.000 claims description 8
208000028017 Psychotic disease Diseases 0.000 claims description 8
206010063837 Reperfusion injury Diseases 0.000 claims description 8
208000006011 Stroke Diseases 0.000 claims description 8
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 8
206010044541 Traumatic shock Diseases 0.000 claims description 8
201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
206010047700 Vomiting Diseases 0.000 claims description 8
230000036506 anxiety Effects 0.000 claims description 8
208000006673 asthma Diseases 0.000 claims description 8
208000002780 macular degeneration Diseases 0.000 claims description 8
201000006417 multiple sclerosis Diseases 0.000 claims description 8
230000004770 neurodegeneration Effects 0.000 claims description 8
208000015122 neurodegenerative disease Diseases 0.000 claims description 8
210000002569 neuron Anatomy 0.000 claims description 8
229910052757 nitrogen Inorganic materials 0.000 claims description 8
201000008482 osteoarthritis Diseases 0.000 claims description 8
230000016087 ovulation Effects 0.000 claims description 8
206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
208000020431 spinal cord injury Diseases 0.000 claims description 8
230000001988 toxicity Effects 0.000 claims description 8
231100000419 toxicity Toxicity 0.000 claims description 8
208000000094 Chronic Pain Diseases 0.000 claims description 7
206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 7
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 7
201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
208000019695 Migraine disease Diseases 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 7
125000003118 aryl group Chemical group 0.000 claims description 7
201000011510 cancer Diseases 0.000 claims description 7
208000033679 diabetic kidney disease Diseases 0.000 claims description 7
208000027866 inflammatory disease Diseases 0.000 claims description 7
230000002401 inhibitory effect Effects 0.000 claims description 7
206010027599 migraine Diseases 0.000 claims description 7
125000001624 naphthyl group Chemical group 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
206010012289 Dementia Diseases 0.000 claims description 6
208000023105 Huntington disease Diseases 0.000 claims description 6
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
208000018737 Parkinson disease Diseases 0.000 claims description 6
201000004681 Psoriasis Diseases 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
206010015037 epilepsy Diseases 0.000 claims description 6
229960005181 morphine Drugs 0.000 claims description 6
208000005298 acute pain Diseases 0.000 claims description 5
125000003710 aryl alkyl group Chemical group 0.000 claims description 5
125000005843 halogen group Chemical group 0.000 claims description 5
229920006395 saturated elastomer Polymers 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 4
125000003282 alkyl amino group Chemical group 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 4
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
101100495911 Arabidopsis thaliana CHR10 gene Proteins 0.000 claims description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
125000002837 carbocyclic group Chemical group 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
208000024827 Alzheimer disease Diseases 0.000 claims 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
MNUHYQZBNHDABI-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexan-6-amine Chemical group C1NCC2C(N)C21 MNUHYQZBNHDABI-UHFFFAOYSA-N 0.000 claims 1
208000031229 Cardiomyopathies Diseases 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
150000003053 piperidines Chemical class 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 4
210000003169 central nervous system Anatomy 0.000 abstract description 2
XDWUSBKLDNVDDQ-UHFFFAOYSA-N 6-phenylpyridin-2-amine Chemical class NC1=CC=CC(C=2C=CC=CC=2)=N1 XDWUSBKLDNVDDQ-UHFFFAOYSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
238000006243 chemical reaction Methods 0.000 description 45
239000000243 solution Substances 0.000 description 38
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 35
238000005160 1H NMR spectroscopy Methods 0.000 description 31
229940093499 ethyl acetate Drugs 0.000 description 30
235000019439 ethyl acetate Nutrition 0.000 description 30
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 27
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
229910001868 water Inorganic materials 0.000 description 22
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
239000003921 oil Substances 0.000 description 19
235000019198 oils Nutrition 0.000 description 19
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
229960003010 sodium sulfate Drugs 0.000 description 18
229910052938 sodium sulfate Inorganic materials 0.000 description 18
235000011152 sodium sulphate Nutrition 0.000 description 18
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
239000012267 brine Substances 0.000 description 15
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
229940073584 methylene chloride Drugs 0.000 description 15
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
239000002904 solvent Substances 0.000 description 13
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
239000002253 acid Substances 0.000 description 12
238000010992 reflux Methods 0.000 description 12
235000011121 sodium hydroxide Nutrition 0.000 description 12
238000000034 method Methods 0.000 description 11
239000000047 product Substances 0.000 description 11
229940083608 sodium hydroxide Drugs 0.000 description 11
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
238000005481 NMR spectroscopy Methods 0.000 description 9
239000012044 organic layer Substances 0.000 description 9
239000007787 solid Substances 0.000 description 9
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
102100022397 Nitric oxide synthase, brain Human genes 0.000 description 7
101710111444 Nitric oxide synthase, brain Proteins 0.000 description 7
239000002585 base Substances 0.000 description 7
239000000499 gel Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 7
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
238000003756 stirring Methods 0.000 description 6
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 5
239000003814 drug Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
239000006260 foam Substances 0.000 description 4
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
229910000041 hydrogen chloride Inorganic materials 0.000 description 4
239000012280 lithium aluminium hydride Substances 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 description 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
239000003513 alkali Substances 0.000 description 3
229940063656 aluminum chloride Drugs 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
239000003999 initiator Substances 0.000 description 3
239000010410 layer Substances 0.000 description 3
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
GZKQXVPTDMGYDX-UHFFFAOYSA-N n-[6-(2-fluoro-4-methylphenyl)pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound FC1=CC(C)=CC=C1C1=CC=CC(NC(=O)C(C)(C)C)=N1 GZKQXVPTDMGYDX-UHFFFAOYSA-N 0.000 description 3
229960002715 nicotine Drugs 0.000 description 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 2
LKUAPSRIYZLAAO-UHFFFAOYSA-N 1-(2-phenylethyl)piperazine Chemical compound C1CNCCN1CCC1=CC=CC=C1 LKUAPSRIYZLAAO-UHFFFAOYSA-N 0.000 description 2
QPUPPPPKBGBGDC-UHFFFAOYSA-N 2,2-dimethyl-n-[6-[4-(oxiran-2-yl)-2-propan-2-yloxyphenyl]pyridin-2-yl]propanamide Chemical compound CC(C)OC1=CC(C2OC2)=CC=C1C1=CC=CC(NC(=O)C(C)(C)C)=N1 QPUPPPPKBGBGDC-UHFFFAOYSA-N 0.000 description 2
ISDGWTZFJKFKMO-UHFFFAOYSA-N 2-phenyl-1,3-dioxane-4,6-dione Chemical compound O1C(=O)CC(=O)OC1C1=CC=CC=C1 ISDGWTZFJKFKMO-UHFFFAOYSA-N 0.000 description 2
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241000700159 Rattus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
235000011114 ammonium hydroxide Nutrition 0.000 description 2
229940043379 ammonium hydroxide Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
208000024732 dysthymic disease Diseases 0.000 description 2
239000000945 filler Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000004312 hexamethylene tetramine Substances 0.000 description 2
235000010299 hexamethylene tetramine Nutrition 0.000 description 2
150000004678 hydrides Chemical class 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
229960004011 methenamine Drugs 0.000 description 2
HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 2
229960003753 nitric oxide Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000007170 pathology Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
241000894007 species Species 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
125000005270 trialkylamine group Chemical group 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
JSGULGGTJKJYKP-UHFFFAOYSA-N (4-methyl-2-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC(C)=CC=C1B(O)O JSGULGGTJKJYKP-UHFFFAOYSA-N 0.000 description 1
125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
MISWEYWXWVUHES-UHFFFAOYSA-N 1-[4-(6-aminopyridin-2-yl)-3-propan-2-yloxyphenyl]-2-(dimethylamino)ethanol Chemical compound CC(C)OC1=CC(C(O)CN(C)C)=CC=C1C1=CC=CC(N)=N1 MISWEYWXWVUHES-UHFFFAOYSA-N 0.000 description 1
RMYMGAHRTBKWBT-UHFFFAOYSA-N 1-[6-amino-2-[4-[1-hydroxy-2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]-2-propan-2-yloxyphenyl]-2h-pyridin-1-yl]-2,2-dimethylpropan-1-one Chemical compound CC(C)OC1=CC(C(O)CN2CCN(CCC=3C=CC=CC=3)CC2)=CC=C1C1C=CC=C(N)N1C(=O)C(C)(C)C RMYMGAHRTBKWBT-UHFFFAOYSA-N 0.000 description 1
SLFNGVGRINFJLK-UHFFFAOYSA-N 1-bromo-2-fluoro-4-methylbenzene Chemical compound CC1=CC=C(Br)C(F)=C1 SLFNGVGRINFJLK-UHFFFAOYSA-N 0.000 description 1
HFCHJYQPPRDMSM-UHFFFAOYSA-N 1-bromo-4-methyl-2-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC(C)=CC=C1Br HFCHJYQPPRDMSM-UHFFFAOYSA-N 0.000 description 1
CTMBKSKRPWBTCB-UHFFFAOYSA-N 2,2-dimethyl-n-[6-(4-methyl-2-propan-2-yloxyphenyl)pyridin-2-yl]propanamide Chemical compound CC(C)OC1=CC(C)=CC=C1C1=CC=CC(NC(=O)C(C)(C)C)=N1 CTMBKSKRPWBTCB-UHFFFAOYSA-N 0.000 description 1
FMSWBDVADBTWDX-UHFFFAOYSA-N 2,2-dimethyl-n-[6-[4-methyl-2-(2-methylpropoxy)phenyl]pyridin-2-yl]propanamide Chemical compound CC(C)COC1=CC(C)=CC=C1C1=CC=CC(NC(=O)C(C)(C)C)=N1 FMSWBDVADBTWDX-UHFFFAOYSA-N 0.000 description 1
PMEIIDDWZIOYKX-UHFFFAOYSA-N 3-[4-(6-aminopyridin-2-yl)-3-fluorophenyl]pyrrolidin-2-one Chemical compound NC1=CC=CC(C=2C(=CC(=CC=2)C2C(NCC2)=O)F)=N1 PMEIIDDWZIOYKX-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
YKMNQNXYSAAQGR-UHFFFAOYSA-N 4-methyl-2-propan-2-yloxyaniline Chemical compound CC(C)OC1=CC(C)=CC=C1N YKMNQNXYSAAQGR-UHFFFAOYSA-N 0.000 description 1
NQXUSSVLFOBRSE-UHFFFAOYSA-N 5-methyl-2-nitrophenol Chemical compound CC1=CC=C([N+]([O-])=O)C(O)=C1 NQXUSSVLFOBRSE-UHFFFAOYSA-N 0.000 description 1
YVTQRJWTWBGGRV-UHFFFAOYSA-N 6-(2-fluoro-4-pyrrolidin-3-ylphenyl)pyridin-2-amine Chemical compound NC1=CC=CC(C=2C(=CC(=CC=2)C2CNCC2)F)=N1 YVTQRJWTWBGGRV-UHFFFAOYSA-N 0.000 description 1
VAKNGUAJSSBUAJ-UHFFFAOYSA-N 6-[2-cyclobutyloxy-4-[2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]phenyl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C(=CC(CCN3CCN(CCC=4C=CC=CC=4)CC3)=CC=2)OC2CCC2)=N1 VAKNGUAJSSBUAJ-UHFFFAOYSA-N 0.000 description 1
FVWIQFODGYGTSF-UHFFFAOYSA-N 6-[2-cyclopentyloxy-4-[2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]phenyl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C(=CC(CCN3CCN(CCC=4C=CC=CC=4)CC3)=CC=2)OC2CCCC2)=N1 FVWIQFODGYGTSF-UHFFFAOYSA-N 0.000 description 1
WUUMDSIFJSDOFP-UHFFFAOYSA-N 6-[2-cyclopropyloxy-4-[2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]phenyl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C(=CC(CCN3CCN(CCC=4C=CC=CC=4)CC3)=CC=2)OC2CC2)=N1 WUUMDSIFJSDOFP-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000007819 coupling partner Substances 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
OZYPPHLDZUUCCI-UHFFFAOYSA-N n-(6-bromopyridin-2-yl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CC(Br)=N1 OZYPPHLDZUUCCI-UHFFFAOYSA-N 0.000 description 1
VSJNBRHKFISDKH-UHFFFAOYSA-N n-[6-(2-fluoro-4-formylphenyl)pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CC(C=2C(=CC(C=O)=CC=2)F)=N1 VSJNBRHKFISDKH-UHFFFAOYSA-N 0.000 description 1
JXTLYBKAQQBEGK-UHFFFAOYSA-N n-[6-(4-formyl-2-propan-2-yloxyphenyl)pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound CC(C)OC1=CC(C=O)=CC=C1C1=CC=CC(NC(=O)C(C)(C)C)=N1 JXTLYBKAQQBEGK-UHFFFAOYSA-N 0.000 description 1
RLGBZQNTCZYCCC-UHFFFAOYSA-N n-[6-[4-(bromomethyl)-2-propan-2-yloxyphenyl]pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound CC(C)OC1=CC(CBr)=CC=C1C1=CC=CC(NC(=O)C(C)(C)C)=N1 RLGBZQNTCZYCCC-UHFFFAOYSA-N 0.000 description 1
BONUBQJVEPJBJI-UHFFFAOYSA-N n-[6-[4-(cyanomethyl)-2-propan-2-yloxyphenyl]pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound CC(C)OC1=CC(CC#N)=CC=C1C1=CC=CC(NC(=O)C(C)(C)C)=N1 BONUBQJVEPJBJI-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
229960000819 sodium nitrite Drugs 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
PCZOZSATUTWXIC-UHFFFAOYSA-N tetraethylazanium;cyanide Chemical compound N#[C-].CC[N+](CC)(CC)CC PCZOZSATUTWXIC-UHFFFAOYSA-N 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
DSNKGSSXSYPWNC-UHFFFAOYSA-O triethylazanium;cyanide Chemical compound N#[C-].CC[NH+](CC)CC DSNKGSSXSYPWNC-UHFFFAOYSA-O 0.000 description 1
VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 1
NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Addiction (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

OA1200000053A 1997-08-28 2000-02-25 Branched alkoxy-substituted 2-aminopyridines as nos inhibitors. OA11294A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5773997P	1997-08-28	1997-08-28

Publications (1)

Publication Number	Publication Date
OA11294A true OA11294A (en)	2003-10-22

Family

ID=22012464

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000053A OA11294A (en)	1997-08-28	2000-02-25	Branched alkoxy-substituted 2-aminopyridines as nos inhibitors.

Country Status (32)

Country	Link
US (2)	US6362195B1 (fr)
EP (1)	EP1007512B1 (fr)
JP (1)	JP3441714B2 (fr)
CN (1)	CN1268122A (fr)
AP (1)	AP9801331A0 (fr)
AR (1)	AR016644A1 (fr)
AT (1)	ATE215532T1 (fr)
AU (1)	AU8458698A (fr)
BR (1)	BR9811921A (fr)
CA (1)	CA2302436C (fr)
DE (1)	DE69804635T2 (fr)
DK (1)	DK1007512T3 (fr)
EA (1)	EA200000165A1 (fr)
ES (1)	ES2172173T3 (fr)
GT (1)	GT199800135A (fr)
HN (1)	HN1998000125A (fr)
HR (1)	HRP980476A2 (fr)
HU (1)	HUP0002803A2 (fr)
ID (1)	ID24318A (fr)
IL (1)	IL134302A0 (fr)
IS (1)	IS5342A (fr)
MA (1)	MA26538A1 (fr)
NO (1)	NO20000957D0 (fr)
OA (1)	OA11294A (fr)
PA (1)	PA8458301A1 (fr)
PE (1)	PE106699A1 (fr)
PL (1)	PL339008A1 (fr)
PT (1)	PT1007512E (fr)
SI (1)	SI1007512T1 (fr)
TN (1)	TNSN98157A1 (fr)
WO (1)	WO1999011620A1 (fr)
ZA (1)	ZA987788B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010049379A1 (en)	1997-08-27	2001-12-06	Lowe John Adams	2-aminopyridines containing fused ring substituents
HUP0103113A3 (en) *	1998-08-11	2002-02-28	Pfizer Prod Inc	New pharmaceutical compositions uses for nos inhibitors
CA2364719C (fr)	1999-02-25	2006-07-04	Pfizer Products Inc.	2-aminopyridines contenant des substituants a cycles condenses
WO2001009307A2 (fr) *	1999-07-30	2001-02-08	University College London	Recherche systematique de modulateurs de synthase d'oxyde nitrique
EP1203098A2 (fr) *	1999-07-30	2002-05-08	University College London	Criblage inductible pour la decouverte de medicaments
GB0004151D0 (en) *	2000-02-23	2000-04-12	Astrazeneca Uk Ltd	Novel use
GB0004149D0 (en)	2000-02-23	2000-04-12	Astrazeneca Uk Ltd	Novel compounds
GB0004153D0 (en)	2000-02-23	2000-04-12	Astrazeneca Uk Ltd	Novel use
GB0004152D0 (en) *	2000-02-23	2000-04-12	Astrazeneca Uk Ltd	Novel compounds
US6469172B2 (en) *	2000-03-08	2002-10-22	Merck & Co., Inc.	Process for the preparation of chemical compounds
SE0102640D0 (sv)	2001-07-31	2001-07-31	Astrazeneca Ab	Novel compounds
US20040077853A1 (en) *	2001-10-10	2004-04-22	Pfizer Inc.	2-amino-6-(2,4,5-substituted-phenyl)-pyridines
AU2003241398A1 (en) *	2002-05-06	2003-11-17	Washington University	Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
WO2005007627A1 (fr) *	2003-07-18	2005-01-27	Nihon Nohyaku Co., Ltd.	Derive de phenylpyridine, produit intermediaire correspondant, et herbicide contenant ledit derive de phenylpyridine en tant qu'ingredient actif
WO2006053109A1 (fr) *	2004-11-10	2006-05-18	Synta Pharmaceuticals Corp.	Composes heteroaryle
US8604031B2 (en) *	2006-05-18	2013-12-10	Mannkind Corporation	Intracellular kinase inhibitors
UA105182C2 (ru)	2008-07-03	2014-04-25	Ньюрексон, Інк.	Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP3002279A1 (fr)	2014-10-02	2016-04-06	Bayer CropScience AG	Procédé de fabrication de dérivés de sulfure 3-(5-aminotriazolyl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5892112A (en) *	1990-11-21	1999-04-06	Glycomed Incorporated	Process for preparing synthetic matrix metalloprotease inhibitors
AU4515696A (en) *	1994-12-12	1996-07-03	Merck & Co., Inc.	Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US5972975A (en) *	1995-12-08	1999-10-26	Merck & Co., Inc.	Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
JP4431638B2 (ja) *	1996-01-29	2010-03-17	アメリカ合衆国	ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
NZ326874A (en) *	1996-03-29	2000-01-28	Pfizer	6-phenylpyridyl-2-amine derivatives
HN1997000027A (es) *	1996-12-06	1997-06-05	Pfizer Prod Inc	Derivados de 6-fenil piridil - 2 amina

1998
- 1998-08-10 HN HN1998000125A patent/HN1998000125A/es unknown
- 1998-08-11 AU AU84586/98A patent/AU8458698A/en not_active Abandoned
- 1998-08-11 PL PL98339008A patent/PL339008A1/xx unknown
- 1998-08-11 CN CN98808459A patent/CN1268122A/zh active Pending
- 1998-08-11 DK DK98935247T patent/DK1007512T3/da active
- 1998-08-11 ES ES98935247T patent/ES2172173T3/es not_active Expired - Lifetime
- 1998-08-11 IL IL13430298A patent/IL134302A0/xx unknown
- 1998-08-11 BR BR9811921-4A patent/BR9811921A/pt not_active Application Discontinuation
- 1998-08-11 US US09/381,887 patent/US6362195B1/en not_active Expired - Fee Related
- 1998-08-11 SI SI9830136T patent/SI1007512T1/xx unknown
- 1998-08-11 CA CA002302436A patent/CA2302436C/fr not_active Expired - Fee Related
- 1998-08-11 EP EP98935247A patent/EP1007512B1/fr not_active Expired - Lifetime
- 1998-08-11 WO PCT/IB1998/001223 patent/WO1999011620A1/fr not_active Ceased
- 1998-08-11 PT PT98935247T patent/PT1007512E/pt unknown
- 1998-08-11 ID IDW20000359A patent/ID24318A/id unknown
- 1998-08-11 JP JP2000508660A patent/JP3441714B2/ja not_active Expired - Fee Related
- 1998-08-11 DE DE69804635T patent/DE69804635T2/de not_active Expired - Fee Related
- 1998-08-11 HU HU0002803A patent/HUP0002803A2/hu unknown
- 1998-08-11 AT AT98935247T patent/ATE215532T1/de not_active IP Right Cessation
- 1998-08-11 EA EA200000165A patent/EA200000165A1/ru unknown
- 1998-08-17 GT GT199800135A patent/GT199800135A/es unknown
- 1998-08-24 PE PE1998000770A patent/PE106699A1/es not_active Application Discontinuation
- 1998-08-26 AR ARP980104258A patent/AR016644A1/es unknown
- 1998-08-26 TN TNTNSN98157A patent/TNSN98157A1/fr unknown
- 1998-08-26 MA MA25230A patent/MA26538A1/fr unknown
- 1998-08-26 PA PA19988458301A patent/PA8458301A1/es unknown
- 1998-08-27 AP APAP/P/1998/001331A patent/AP9801331A0/en unknown
- 1998-08-27 ZA ZA9807788A patent/ZA987788B/xx unknown
- 1998-08-28 HR HR60/057,739A patent/HRP980476A2/hr not_active Application Discontinuation
2000
- 2000-01-14 IS IS5342A patent/IS5342A/is unknown
- 2000-02-25 OA OA1200000053A patent/OA11294A/en unknown
- 2000-02-25 NO NO20000957A patent/NO20000957D0/no not_active Application Discontinuation
2001
- 2001-09-20 US US09/957,398 patent/US20020022642A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR016644A1 (es)	2001-07-25
US6362195B1 (en)	2002-03-26
WO1999011620A1 (fr)	1999-03-11
IS5342A (is)	2000-01-14
CA2302436A1 (fr)	1999-03-11
PA8458301A1 (es)	2000-05-24
DE69804635T2 (de)	2002-07-18
ES2172173T3 (es)	2002-09-16
DE69804635D1 (de)	2002-05-08
NO20000957L (no)	2000-02-25
BR9811921A (pt)	2000-08-15
EA200000165A1 (ru)	2000-10-30
ZA987788B (en)	2000-02-28
DK1007512T3 (da)	2002-07-08
NO20000957D0 (no)	2000-02-25
PE106699A1 (es)	1999-11-02
IL134302A0 (en)	2001-04-30
JP3441714B2 (ja)	2003-09-02
ID24318A (id)	2000-07-13
HN1998000125A (es)	1999-02-09
AP9801331A0 (en)	2000-02-27
US20020022642A1 (en)	2002-02-21
ATE215532T1 (de)	2002-04-15
AU8458698A (en)	1999-03-22
CN1268122A (zh)	2000-09-27
TNSN98157A1 (fr)	2005-03-15
EP1007512B1 (fr)	2002-04-03
PT1007512E (pt)	2002-07-31
JP2001514252A (ja)	2001-09-11
HRP980476A2 (en)	1999-06-30
SI1007512T1 (en)	2002-10-31
PL339008A1 (en)	2000-12-04
MA26538A1 (fr)	2004-12-20
HUP0002803A2 (hu)	2001-06-28
GT199800135A (es)	2000-02-08
CA2302436C (fr)	2003-10-07
EP1007512A1 (fr)	2000-06-14

Publication	Publication Date	Title
ES2206691T3 (es)	2004-05-16	Derivados de 6-fenilpiridil-2-amina utiles como inhibidores de nos.
EP1007512B1 (fr)	2002-04-03	2-aminopyridines alcoxy-substituees ramifiees, utilisees comme inhibiteurs de nos
ES2200813T3 (es)	2004-03-16	2-aminopiridinas que contienen sustituyentes de anillo condesado.
EP1084109B1 (fr)	2005-01-26	2-aminopyridines contenant des substituants a anneaux condenses et convenant comme inhibiteurs de synthase de l'oxyde nitrique
OA11595A (en)	2004-08-19	New pharmaceutical uses for NOS inhibitors.
ES2275917T3 (es)	2007-06-16	2-amino-6-(fenil-2,4,5-sustituido)-piridinas para usar como inhibidores de la oxido nitrico sintasa.
MXPA00002028A (en)	2001-05-17	Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors
US20040142924A1 (en)	2004-07-22	6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors